Suchergebnisse - "Arranz, José Ángel"

PubPharm (55)

1

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer

enthalten in: Cell reports. Medicine | 2024

von Galsky, M. | Guan, X. | Rishipathak, D. | +30

2

Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment : Relationship Between Antibodies and Severity of Thyroid Dysfunction

enthalten in: Endocrine, metabolic & immune disorders drug targets | 2024

von Miguélez González, M. | Galdón Sanz-Pastor, A. | Áñez Gómez, R. | +13

3

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

enthalten in: European urology open science | 2023

von Grande, E. | Bamias, A. | Galsky, M. | +16

4

Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting

enthalten in: Cancers | 2022

von Garrido Siles, M. | López-Beltran, A. | Pelechano, P. | +8

5

Recent therapeutic advances in urothelial carcinoma : A paradigm shift in disease management

enthalten in: Critical reviews in oncology/hematology | 2022

von Bellmunt, J. | Valderrama, B. | Puente, J. | +9

6

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer : The VIABLE Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2022

von Vogelzang, N. | Beer, T. | Gerritsen, W. | +124

CommentIn: JAMA Oncol. 2022 Apr 1;8(4):522-523. - PMID 35142797

7

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

enthalten in: The New England journal of medicine | 2021

von Choueiri, T. | Powles, T. | Burotto, M. | +129

CommentIn: Eur Urol. 2021 Aug;80(2):256-257. - PMID 33992475

8

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Powles, T. | van der Heijden, M. | Castellano, D. | +127

ErratumIn: Lancet Oncol. 2021 Jan;22(1):e5. - PMID 33387509

9

De-escalation : Testicular cancer.

enthalten in: Archivos espanoles de urologia | 2020

von Mayor, J. | Álvarez-Maestro, M. | Arranz, J. | +1

10

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

enthalten in: The New England journal of medicine | 2019

von Loriot, Y. | Necchi, A. | Park, S. | +119

CommentIn: Nat Rev Clin Oncol. 2019 Oct;16(10):591. - PMID 31406342

1
2
3
4
5
6
Nächster »
[6]